GSK and Targacept partners in pain
Executive Summary
GlaxoSmithKline will gain access to Targacept's two lead candidates for pain: TC-2696, currently in a Phase II post-operative pain study in molar extraction patients, and TC-6499, a preclinical candidate for neuropathic pain, under a deal announced July 27. Partnership includes drugs targeting neuronal nicotinic receptors spanning five therapeutic areas, which also include smoking cessation, obesity, addiction and Parkinson's disease. Deal has a potential value of $1.5 million in addition to an upfront payment of $35 million. Program will be overseen by GSK's Center of Excellence for External Drug Discovery, with Targacept responsible for development of candidates through Phase II proof of concept. AstraZeneca has also partnered with Targacept on an NNR candidate for Alzheimer's, which is in Phase IIb (1"The Pink Sheet," Feb. 6, 2006, p. 19)...
You may also be interested in...
AstraZeneca Expands Pipeline With “Reduced Risk” Phase III Program
AstraZeneca is entering 2006 with an expanded, lower risk Phase III pipeline that concentrates on familiar therapeutic categories
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.